Table 2. Risk of female breast cancer, by ADH1B and ALDH2 genotype.
| Cases /Controls |
OR-1a
(95% CI) |
OR-2b
(95% CI) |
|
| ADH1B | |||
| (*2:rapid/*2:rapid) | 265/539 | 1 (ref.) | 1 (ref.) |
| (*1:slow/*2:rapid) | 162/322 | 1.02 (0.81–1.3) | 1.05 (0.82–1.34) |
| (*1:slow/*1:slow) | 25/47 | 1.08 (0.65–1.79) | 1.15 (0.69–1.94) |
| Unknown | 4/4 | ||
| Ptrendc | 0.75 | 0.541 | |
| ALDH2 | |||
| (*1:active/*1:active) | 222/455 | 1 (ref.) | 1 (ref.) |
| (*1:active/*2:null) | 196/362 | 1.11 (0.88–1.41) | 1.08 (0.83–1.39) |
| (*2:null/*2:null) | 38/93 | 0.83 (0.55–1.25) | 0.77 (0.49–1.19) |
| Unknown | 0/2 | ||
| Ptrendc | 0.846 | 0.568 | |
aLogistic regression model controlling for matching factors only.
bLogistic regression model controlling for matching factors plus alcohol consumption, smoking status, body-mass index, regular exercise, family history of breast cancer, age at menarche, parity, hormone-replacement therapy, and mode of referral to hospital.
cTrends for genotypes were assessed by a test that used scores for each genotype (0, homozygous genotype for reference allele; 1, heterozygous genotype; and 2, homozygous genotype for nonreference allele).